{"id":"sertindole","rwe":[{"pmid":"41591671","year":"2026","title":"Exploring the key molecular mechanisms and immune microenvironment of oxidative stress-related pathways in pancreatic neuroendocrine tumor combining scRNA-seq and bulk RNA.","finding":"","journal":"Discover oncology","studyType":"Clinical Study"},{"pmid":"41231853","year":"2025","title":"Mining and analysis of drug-induced shock adverse reactions: A comprehensive pharmacovigilance study based on the US FAERS database.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"40839626","year":"2025","title":"Sexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis.","finding":"","journal":"PloS one","studyType":"Clinical Study"},{"pmid":"40505199","year":"2025","title":"Automated phenotypic analysis and classification of drug-treated cardiomyocytes via synergized time-lapse holographic imaging and deep learning.","finding":"","journal":"Computer methods and programs in biomedicine","studyType":"Clinical Study"},{"pmid":"40056667","year":"2025","title":"Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis.","finding":"","journal":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology","studyType":"Clinical Study"}],"tags":[{"label":"sertindole","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"5-hydroxytryptamine receptor 2C","category":"target"},{"label":"HTR2C","category":"gene"},{"label":"DRD2","category":"gene"},{"label":"HRH1","category":"gene"},{"label":"N05AE03","category":"atc"},{"label":"Active","category":"status"},{"label":"Schizophrenia","category":"indication"},{"label":"H. Lundbeck A/S","category":"company"},{"label":"Antipsychotic Agents","category":"pharmacology"},{"label":"Central Nervous System Agents","category":"pharmacology"},{"label":"Central Nervous System Depressants","category":"pharmacology"},{"label":"Psychotropic Drugs","category":"pharmacology"},{"label":"Tranquilizing Agents","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"company":"H. Lundbeck A/S","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=SERTINDOLE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:12:19.736719+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:12:27.907520+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SERTINDOLE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:12:28.820994+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Serotonin 2 receptors; 5-HT2a & 5-HT2c antagonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:29.394358+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL12713/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:12:29.290327+00:00"}},"allNames":"zerdol","offLabel":[],"synonyms":["sertindole hydrochloride","sertindole HCl","Lu-23-174","Lu 23-174","sertindole","serdolect","zerdol"],"timeline":[{"date":"1996-05-23","type":"positive","source":"DrugCentral","milestone":"UK Medicines and Healthcare Products Regulatory Agency (MHRA) approval (H. Lundbeck A/S)"}],"approvals":[{"date":"1996-05-23","orphan":false,"company":"H. Lundbeck A/S","regulator":"UK Medicines and Healthcare Products Regulatory Agency (MHRA)"}],"brandName":"Zerdol","ecosystem":[{"indication":"Schizophrenia","otherDrugs":[{"name":"aripiprazole","slug":"aripiprazole","company":"Otsuka"},{"name":"aripiprazole lauroxil","slug":"aripiprazole-lauroxil","company":"Alkermes"},{"name":"asenapine","slug":"asenapine","company":"Forest Labs Inc"},{"name":"brexpiprazole","slug":"brexpiprazole","company":"Otsuka Pharm Co Ltd"}],"globalPrevalence":24000000}],"mechanism":{"target":"5-hydroxytryptamine receptor 2C","targets":[{"gene":"HTR2C","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2C","protein":"5-hydroxytryptamine receptor 2C"},{"gene":"DRD2","source":"DrugCentral","target":"D(2) dopamine receptor","protein":"D(2) dopamine receptor"},{"gene":"HRH1","source":"DrugCentral","target":"Histamine H1 receptor","protein":"Histamine H1 receptor"},{"gene":"HTR2A","source":"DrugCentral","target":"5-hydroxytryptamine receptor 2A","protein":"5-hydroxytryptamine receptor 2A"},{"gene":"ADRA1A","source":"DrugCentral","target":"Alpha-1A adrenergic receptor","protein":"Alpha-1A adrenergic receptor"},{"gene":"DRD3","source":"DrugCentral","target":"D(3) dopamine receptor","protein":"D(3) dopamine receptor"},{"gene":"KCNH2","source":"DrugCentral","target":"Potassium voltage-gated channel subfamily H member 2","protein":"Potassium voltage-gated channel subfamily H member 2"},{"gene":"HTR6","source":"DrugCentral","target":"5-hydroxytryptamine receptor 6","protein":"5-hydroxytryptamine receptor 6"},{"gene":"DRD4","source":"DrugCentral","target":"D(4) dopamine receptor","protein":"D(4) dopamine receptor"},{"gene":"HTR7","source":"DrugCentral","target":"5-hydroxytryptamine receptor 7","protein":"5-hydroxytryptamine receptor 7"}],"modality":"Small Molecule","drugClass":"sertindole","explanation":"","oneSentence":"","technicalDetail":"Sertindole acts as a selective antagonist at the 5-HT2C receptor, which is involved in the regulation of mood, cognition, and perception."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2435","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=SERTINDOLE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=SERTINDOLE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T15:37:08.064535","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:31.195402+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"molindone","drugSlug":"molindone","fdaApproval":"1974-01-18","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"ziprasidone","drugSlug":"ziprasidone","fdaApproval":"2001-02-05","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lurasidone","drugSlug":"lurasidone","fdaApproval":"2010-10-28","patentExpiry":"Nov 26, 2026","patentStatus":"Patent protected","relationship":"same-class"}],"genericName":"sertindole","indications":{"approved":[{"name":"Schizophrenia","source":"DrugCentral","snomedId":58214004,"regulator":"FDA","usPrevalence":2800000,"globalPrevalence":24000000,"prevalenceMethod":"curated","prevalenceSource":"WHO, 2022"}],"offLabel":[],"pipeline":[]},"_mhraChecked":true,"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"molindone","brandName":"molindone","genericName":"molindone","approvalYear":"1974","relationship":"same-class"},{"drugId":"ziprasidone","brandName":"ziprasidone","genericName":"ziprasidone","approvalYear":"2001","relationship":"same-class"},{"drugId":"lurasidone","brandName":"lurasidone","genericName":"lurasidone","approvalYear":"2010","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT01498770","phase":"","title":"An Observational Drug Utilization Study of Asenapine in the United Kingdom (P08308)","status":"COMPLETED","sponsor":"Organon and Co","startDate":"2013-04-01","conditions":["Bipolar Disorder"],"enrollment":42,"completionDate":"2017-12-21"},{"nctId":"NCT02435095","phase":"PHASE4","title":"Antipsychotic Induced Structural and Functional Brain Changes","status":"TERMINATED","sponsor":"RWTH Aachen University","startDate":"2015-05","conditions":["Schizophrenia"],"enrollment":174,"completionDate":"2020-08"},{"nctId":"NCT02021201","phase":"PHASE4","title":"The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia","status":"TERMINATED","sponsor":"Birte Glenthoj","startDate":"2008-07","conditions":["Schizophrenia"],"enrollment":1,"completionDate":"2013-07"},{"nctId":"NCT02307396","phase":"PHASE4","title":"Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics in Schizophrenic Patients","status":"COMPLETED","sponsor":"Technical University of Munich","startDate":"2015-02-01","conditions":["Schizophrenia","Schizophrenia and Disorders With Psychotic Features","Schizoaffective Disorders"],"enrollment":21,"completionDate":"2016-06-22"},{"nctId":"NCT02374567","phase":"PHASE3","title":"Pharmacovigilance in Gerontopsychiatric Patients","status":"TERMINATED","sponsor":"Hannover Medical School","startDate":"2015-01","conditions":["Dementia","Depression","Schizophrenia","Psychosomatic Disorders","Anxiety Disorders"],"enrollment":407,"completionDate":"2017-06-28"},{"nctId":"NCT00763438","phase":"PHASE4","title":"Safety Study of an Antipsychotic, Sertindole, to Treat Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-11","conditions":["Schizophrenia"],"enrollment":18,"completionDate":"2010-10"},{"nctId":"NCT01765829","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy of Treatment vs Discontinuation in a First Episode of Non-affective Psychosis","status":"UNKNOWN","sponsor":"Fundación Pública Andaluza Progreso y Salud","startDate":"2012-11","conditions":["Psychosis Nos/Other"],"enrollment":104,"completionDate":"2015-11"},{"nctId":"NCT00654706","phase":"PHASE3","title":"Efficacy Study Exploring the Effects on Cognition of Sertindole Versus Comparator in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2008-03","conditions":["Schizophrenia","Cognition"],"enrollment":264,"completionDate":"2010-03"},{"nctId":"NCT00759460","phase":"PHASE3","title":"Study on Metabolic Parameters of Sertindole in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-03","conditions":["Schizophrenia"],"enrollment":250,"completionDate":"2008-04"},{"nctId":"NCT00864045","phase":"PHASE3","title":"Sertindole in Asian Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2007-03","conditions":["Schizophrenia"],"enrollment":394,"completionDate":"2008-05"},{"nctId":"NCT00759421","phase":"PHASE3","title":"Exploratory Cognition Study of Sertindole in Patients With Schizophrenia","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2006-10","conditions":["Schizophrenia"],"enrollment":96,"completionDate":"2008-04"},{"nctId":"NCT00885690","phase":"NA","title":"Comparing the Effects of Sertindole and Olanzapine on Cognition (SEROLA)","status":"TERMINATED","sponsor":"University of Aarhus","startDate":"2009-04","conditions":["Schizophrenia"],"enrollment":11,"completionDate":"2012-11"},{"nctId":"NCT00629252","phase":"NA","title":"The Effect of Sertindole on Sensory Gating and Cognition in Schizophrenic Patients","status":"TERMINATED","sponsor":"University of Zurich","startDate":"2008-02","conditions":["Schizophrenia"],"enrollment":14,"completionDate":"2012-08"},{"nctId":"NCT00612079","phase":"NA","title":"The Effect of Sertindole on Sensory Gating and Cognition in Healthy Volunteers","status":"COMPLETED","sponsor":"University of Zurich","startDate":"2007-09","conditions":["Healthy"],"enrollment":30,"completionDate":"2008-11"},{"nctId":"NCT00856583","phase":"PHASE3","title":"Safety Study of Sertindole Versus Risperidone Under Normal Conditions of Use","status":"COMPLETED","sponsor":"H. Lundbeck A/S","startDate":"2002-07","conditions":["Schizophrenia"],"enrollment":9809,"completionDate":"2008-02"},{"nctId":"NCT00345982","phase":"NA","title":"Augmenting Clozapine With Sertindole - SERCLOZ","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2006-09","conditions":["Schizophrenia"],"enrollment":50,"completionDate":"2010-09"},{"nctId":"NCT00480844","phase":"PHASE4","title":"Comparison of Cognitive Functions of Schizophrenic Patients Treated With Sertindole Versus Risperidone","status":"UNKNOWN","sponsor":"Sheba Medical Center","startDate":"2008-10","conditions":["Schizophrenia"],"enrollment":60,"completionDate":""}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NUI":"N0000179296","NDDF":"006145","UNII":"GVV4Z879SP","VUID":"4025271","CHEBI":"CHEBI:9122","VANDF":"4025271","INN_ID":"6455","RXNORM":"152894","UMLSCUI":"C0084528","chemblId":"CHEMBL12713","ChEMBL_ID":"CHEMBL12713","KEGG_DRUG":"D00561","DRUGBANK_ID":"DB06144","PUBCHEM_CID":"60149","SNOMEDCT_US":"321603004","IUPHAR_LIGAND_ID":"98","MESH_SUPPLEMENTAL_RECORD_UI":"C066304"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"H. Lundbeck A/S","relationship":"Original Developer"}],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"74%"},"publicationCount":483,"therapeuticAreas":["Neuroscience"],"atcClassification":{"source":"DrugCentral","atcCode":"N05AE03","allCodes":["N05AE03"]},"biosimilarFilings":[],"originalDeveloper":"H. Lundbeck A/S","recentPublications":[{"date":"2026 Jan 27","pmid":"41591671","title":"Exploring the key molecular mechanisms and immune microenvironment of oxidative stress-related pathways in pancreatic neuroendocrine tumor combining scRNA-seq and bulk RNA.","journal":"Discover oncology"},{"date":"2025","pmid":"41231853","title":"Mining and analysis of drug-induced shock adverse reactions: A comprehensive pharmacovigilance study based on the US FAERS database.","journal":"PloS one"},{"date":"2025","pmid":"40839626","title":"Sexual dysfunctions related to use of antipsychotics: A protocol for a systematic review and meta-analysis.","journal":"PloS one"},{"date":"2025 Sep","pmid":"40505199","title":"Automated phenotypic analysis and classification of drug-treated cardiomyocytes via synergized time-lapse holographic imaging and deep learning.","journal":"Computer methods and programs in biomedicine"},{"date":"2025 May","pmid":"40056667","title":"Antipsychotic drug dosing and study discontinuation in schizophrenia: A systematic review and dose-response meta-analysis.","journal":"European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"withdrawn","companyName":"H. Lundbeck A/S","companyId":"h-lundbeck-a-s","modality":"Small molecule","firstApprovalDate":"1996","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"UK Medicines and Healthcare Products Regulatory Agency (MHRA)","status":"approved","approval_date":"1996-05-23T00:00:00.000Z","mah":"H. Lundbeck A/S","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:12:31.195402+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}